Biomarker Services

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.

A range of antigen-specific and non-specific cell-based assays can be adapted for immunological drug development services in the following categories:

• Predicting effective concentrations of single and multiple-drug regimens.
• Design and development of cell-based companion diagnostics.
• Surrogate endpoint development.
• Assay validation and performance assessment.

Assay and support capabilities include:

• Pathogen- and mitogen-specific immune responses
• Antiviral (cellular) immunity
• T- and B-cell subset sensitivity to drugs and apoptosis
• Antigen presentation
• Cryopreservation
• Contract research
• GLP- and GMP-compliance

Plexision can also assist drug developers in regulatory submissions for biomarker qualification.

If you would like to know more about our research capabilities, please contact us at info@plexision.com.

References

1. Sindhi R, Allaert J, Gladding D, Haaland P, Koppelman B, Dunne J, Sehgal S. Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications. J Immunol Methods. 2003 Jan 15;272(1- 2):257-72. PMID: 12505729.

2. Sindhi R, Berry V, Janosky J. Multiparametric effect: concentration analyses. Front Biosci. 2004 May 1;9:1218-21. Review. PMID: 14977538

3. Berry V, Magill A, Yost M, Janosky J, Sindhi R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A. 2006 Feb;69(2):95-103.PMID:16369935

4. Sindhi R, Allaert J, Gladding D, Koppelman B, Dunne JF. Cytokines and cell surface receptors as target end points of immunosuppression with cyclosporine A. J Interferon Cytokine Res. 2001 Jul;21(7):507-14. PMID: 11506745.

5. Sindhi R, LaVia MF, Paulling E, McMichael J, Burckart G, Shaw S, Sindhi LA, Livingston R, Sehgal S, Jaffe J. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation. 2000 Feb 15;69(3):432-6. PMID: 10706056

6. Longui CA, Santos MC, Formiga CB, Oliveira DV, Rocha MN, Faria CD, Kochi C, Monte O. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory andimmunosuppressive properties. Arq Bras Endocrinol Metabol. 2005 Jun;49(3):378-83. Epub 2006 Mar 16. PMID: 16543991

7. Fukudo M, Yano I, Masuda S, Katsura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K. Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. Liver Transpl. 2006 Feb;12(2):292-300.PMID: 16447186

8. Vethe NT, Bremer S, Rootwelt H, Bergan S. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit. 2008 Dec;30(6):647-55. doi: 10.1097/FTD.0b013e31818955c3. PMID: 18806697

9. Ningappa M, Ashokkumar C, Higgs BW, Sun Q, Jaffe R, Mazariegos G, Li D, Weeks DE, Subramaniam S, Ferrell R, Hakonarson H, Sindhi R. Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection. Am J Transplant. 2016 Feb;16(2):497-508. doi: 10.1111/ajt.13509. Epub 2015 Dec 11. PMID: 26663361

10. Ashokkumar C, Ganguly B, Townsend R, White J, Levy S, Moritz M, Mazariegos G, Sun Q, Sindhi R. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens. Sci Rep. 2015 Oct 16;5:15218. doi: 10.1038/srep15218. PMID: 26472085